In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Piper Sandler analyst David Amsellem maintained a Hold rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target ...
Hosted on MSN12mon
Teva upgraded to Overweight at Piper Sandler on multiple expansionTeva Pharmaceutical (NYSE:TEVA) traded higher in the morning hours Monday after Piper Sandler upgraded ... margin recovery/ expansion. Analyst David Amsellem notes that his firm hasn't issued ...
Hosted on MSN1mon
Biogen cut to neutral at Piper Sandler on Alzheimer’s headwindsPiper Sandler downgraded Biogen (NASDAQ ... Alzheimer's disease franchise (an uphill battle in our view)," Piper analyst David Amsellem wrote, adding, "We remain cautious on the AD franchise ...
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
On Thursday, Piper Sandler analyst David Amsellem adjusted the price target for Sage Therapeutics (NASDAQ:SAGE) stock, reducing it significantly to $9 from the previous $26 while maintaining an ...
On Thursday, Piper Sandler analyst David Amsellem adjusted the price target for Sage (LON:SGE) Therapeutics (NASDAQ:SAGE) stock, reducing it significantly to $9 from the previous $26 while maintaining ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback